首页|噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效研究

噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效研究

扫码查看
目的 探讨噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效.方法 选择2015年3月~2016年2月在浙江金华广福医院呼吸科门诊就诊的COPD稳定期患者84例,随机分为对照组及治疗组,对照组在基础治疗上用舒利迭,治疗组在对照组的基础上加用噻托溴铵吸入剂,比较2组患者的治疗半年后的肺功能、血气分析结果、6min步行距离,呼吸困难评分以及生活质量.结果 治疗组在治疗后半年FVC、FEV1以及FEV1/FVC(%)较对照组显著升高(P<0.05).治疗组治疗半年后患者生活质量评分以及呼吸困难积分显著低于对照组(P<0.05).治疗组患者6MWD在治疗后显著长于对照组(P<0.05).治疗组在治疗后半年PaCO2较对照组显著降低,而PaO2较对照组显著升高(P<0.05).结论 噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者,能有效的改善换的肺功能,提高生活质量,以及降低呼吸困难等临床症状.
Clinical research of tiotropium bromide combined with seretide in patients with chronic obstructive pulmonary disease at stable period
ObjectiveTo explore the Clinical effect of Tiotropium Bromide combined with seretide in patients with chronic obstructive pulmonary disease at stable period.Methods84 patients with stable COPD from March 2015 to February 2016 in our hospital outpatient respiratory department were randomly divided into control group and treatment group.The control group was treated with Seretide, the treatment group was treated withtiotropium bromide on the basis of control group.Compared the lung function, blood gas analysis, 6-minute walking distance, dyspnea score and quality of life were between the two groups after six months of treatment.ResultsFVC, FEV1and FEV1/ FVC (%) in the treatment group were significantly higher than those in the control group (P<0.05).The score of quality of life and dyspnea in the treatment group were significantly lower than those in the control group (P<0.05).The 6MWD in treatment group was significantly longer than that in control group (P<0.05).PaCO2 was significantly lower in the treatment group than that in the control group, but PaO2 was significantly higher than that in the control group after six months treated(P<0.05).ConclusionThe combination of tiotropium bromide and seretide in patients with chronic obstructive pulmonary disease (COPD) is effective in improving pulmonary function, improving life therapy, and reducing the symptoms of dyspnea.

TiotropiumBromideseretidechronic obstructive pulmonary diseasestable periodclinical efficacy

吴晓虞、何六涛、陈华春

展开 >

浙江金华广福医院呼吸内科,浙江金华321000

噻托溴铵 舒利迭 慢性阻塞性肺疾病 稳定期 临床疗效

金华市科技计划项目

2012-3-019

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(5)
  • 16
  • 2